Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and Aurora Cannabis (NASDAQ:ACB – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares Bio-Rad Laboratories and Aurora Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 29.42% | 3.86% | 2.70% |
| Aurora Cannabis | -23.46% | -0.04% | -0.03% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Bio-Rad Laboratories and Aurora Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 1 | 2 | 3 | 0 | 2.33 |
| Aurora Cannabis | 1 | 1 | 1 | 0 | 2.00 |
Institutional and Insider Ownership
65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 17.8% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Bio-Rad Laboratories and Aurora Cannabis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 2.81 | $759.90 million | $27.91 | 9.65 |
| Aurora Cannabis | $246.72 million | 0.87 | $1.63 million | ($1.08) | -3.51 |
Bio-Rad Laboratories has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Bio-Rad Laboratories has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Summary
Bio-Rad Laboratories beats Aurora Cannabis on 14 of the 14 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About Aurora Cannabis
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
